<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595295</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_HMA Register</org_study_id>
    <nct_id>NCT01595295</nct_id>
  </id_info>
  <brief_title>Registry on Hypomethylating Agents in Myeloid Neoplasms</brief_title>
  <official_title>Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelominocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is set up to collect real-world experience in the management of patients with
      myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with
      hypomethylating agents in Austria and potentially other participating countries. This
      registry will collect data in a retrospective as well as in a prospective manner at various
      sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a
      routine clinical setting in patients with various comorbidities.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response evaluation</measure>
    <time_frame>up to 10 years</time_frame>
    <description>hematological response, marrow response, cytogenetic response (if data is available), quantification of reduced need for transfusions, median response duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Documentation of adverse events and toxicities</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment cycles</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and reasons of dose reductions</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uni/multivariate analysis of various factors known or thought to influence overall survival in order to establish prognostic markers</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Hypomethylating Agents</arm_group_label>
    <description>Patients treated with hypomethylating agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non interventional</intervention_name>
    <arm_group_label>Hypomethylating Agents</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      From some patients with myeloid neoplasms blood or tissue samples will be stored for further
      analyses. These samples will also be obtained from patients, who are not or not yet treated
      with hypomethylating agents, to comprise a control.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with MDS, CMML, and AML, who begin with or already have received treatment with a
        hypomethylating agent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with MDS, CMML, and AML

          -  who begin with or already have received treatment with with a hypomethylating agent

          -  who are willing to provide informed consent

        Exclusion Criteria:

          -  Due to the non-interventional design of this program there are no specific exclusion
             criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Greil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik für Innere Medizin III der PMU Salzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Greil, MD</last_name>
    <phone>+43 662 4482</phone>
    <phone_ext>2879</phone_ext>
    <email>r.greil@salk.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Pleyer, MD</last_name>
    <phone>+43 662 4482</phone>
    <phone_ext>58271</phone_ext>
    <email>l.pleyer@salk.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Fürstenfeld</name>
      <address>
        <city>Fürstenfeld</city>
        <zip>8280</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UK Graz: Universitätsklinik für Innere Medizin; Klinische Abteilung für Hämatologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin V</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt: 1. Medizinische Abteilung</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UK Krems: Innere Medizin II</name>
      <address>
        <city>Krems an der Donau</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BHS Linz: Interne I</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabethinen Linz: I. Interne Abteilung</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin III Universitätsklinik für Innere Medizin III der PMU Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels Grieskirchen</name>
      <address>
        <city>Wels</city>
        <zip>600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rudolfstiftung: 4. Medizinische Abteilung</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH Meduni Wien: Universitätsklinik für Innere Medizin I: Klinische Abteilung für Hämatologie und Hämostaseologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hietzing</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital Wien</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Donauspital: 3. Medizinische Abteilung</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Croatia</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMML</keyword>
  <keyword>MDS</keyword>
  <keyword>AML</keyword>
  <keyword>registry</keyword>
  <keyword>Vidaza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

